Your browser doesn't support javascript.
loading
Molecular Targeting of Cancer-Associated PCNA Interactions in Pancreatic Ductal Adenocarcinoma Using a Cell-Penetrating Peptide.
Smith, Shanna J; Li, Caroline M; Lingeman, Robert G; Hickey, Robert J; Liu, Yilun; Malkas, Linda H; Raoof, Mustafa.
Afiliación
  • Smith SJ; Department of Molecular and Cellular Biology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
  • Li CM; Department of Molecular and Cellular Biology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
  • Lingeman RG; Department of Molecular and Cellular Biology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
  • Hickey RJ; Department of Molecular Pharmacology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
  • Liu Y; Department of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
  • Malkas LH; Department of Molecular and Cellular Biology, Beckman Research Institute at City of Hope, Duarte, CA 91010, USA.
  • Raoof M; Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
Mol Ther Oncolytics ; 17: 250-256, 2020 Jun 26.
Article en En | MEDLINE | ID: mdl-32368614
ABSTRACT
Pancreatic ductal adenocarcinoma is a particularly difficult cancer to treat due to a lack of effective screening or treatment. Pancreatic cancer cells exhibit high proliferating cell nuclear antigen (PCNA) expression, which is associated with poor prognosis. PCNA, an important nuclear DNA replication and repair protein, regulates a myriad of proteins via the interdomain connector loop. Within this region, amino acids 126-133 are critical for PCNA interactions in cancer cells. Here, we investigate the ability of a decoy cell-penetrating peptide, R9-caPeptide, that mimics the interdomain connector loop region of PCNA to disrupt PCNA-protein interactions in pancreatic cancer cells. Our data suggest that R9-caPeptide causes dose-dependent toxicity in a panel of pancreatic cancer cell lines by inhibiting DNA replication fork progression and PCNA-regulated DNA repair, ultimately causing lethal DNA damage. Overall, these studies lay the foundation for novel therapeutic strategies that target PCNA in pancreatic cancer.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Mol Ther Oncolytics Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Mol Ther Oncolytics Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos